Epoetin alfa - Kirin-Amgen

Drug Profile

Epoetin alfa - Kirin-Amgen

Alternative Names: Epoetin - Amgen; Epoetin-α; Epogen; Epoimmun; Eprex; Erypo; Espo; Kirin EPO; KRN-5702; Li Xue Bao; Procrit; r-HuEPO; recombinant human EPO; recombinant human erythropoietin

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Kirin-Amgen
  • Developer Janssen Biotech; Johnson & Johnson; Kyowa Hakko Kirin; Weihai Sinogen Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • No development reported Neurological disorders; Stroke

Most Recent Events

  • 24 Mar 2017 Agence Nationale de Sécurité du Médicament et des Produits de Santé approves epoetin alfa for symptomatic Anaemia in adult patients with primary myelodysplastic syndromes in France
  • 13 Jun 2016 Efficacy and adverse events data from a phase III trial in Anaemia presented at the 21st Annual Congress of the European Hematology Association (EHA-2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top